At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Aug 16, 2026 at 20:35 ET
Mesoblast completed patient treatment in the pivotal Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease, randomizing and treating 350 patients. Top-line results are expected in mid-CY2027. The trial has RMAT designation from the FDA, enabling priority review upon BLA filing.
- Completed patient treatment in pivotal Phase 3 trial MSB-DR004 for rexlemestrocel-L in chronic low back pain (CLBP) associated with degenerative disc disease.
- 350 patients randomized and treated with either rexlemestrocel-L or sham injection.
- Primary endpoint is durable pain reduction at 12 months; secondary endpoints include function, quality of life, and opioid cessation.
- Rexlemestrocel-L has FDA Regenerative Medicine Advanced Therapy (RMAT) designation, allowing priority review upon BLA filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access